Education
About Us
Working with TipRanks
Follow Us
Relmada Therapeutics (RLMD)
NASDAQ:RLMD
RLMD Stock Chart & Stats
$3.88
-$0.01(-3.06%)
At close: 4:00 PM EST
$3.88
-$0.01(-3.06%)
Day’s Range― - ―
52-Week Range$0.24 - $5.12
Previous CloseN/A
Volume447.03K
Average Volume (3M)532.69K
Market Cap
$284.53M
Enterprise Value$283.15M
Total Cash (Recent Filing)$13.89M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.86
Next Earnings
Mar 24, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding73,333,626
10 Day Avg. Volume598,383
30 Day Avg. Volume532,694
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.44
Price to Sales (P/S)0.00
P/FCF Ratio-0.30
Enterprise Value/Market Cap1.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-7.35
Forecast
1Y Price Target
$9.00Price Target Upside131.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessNDV-01 for high-grade non-muscle invasive bladder cancer showed an overall response rate of 85% and high-grade recurrence-free survival in patients with papillary disease of 83%.
Competitive AdvantageNDV-01's novel sustained-release formulation could have blockbuster potential due to its ease of administration and increased efficacy.
Market OpportunityThe in-licensing of NDV-01 for treating NMIBC represents a multi-billion opportunity for Relmada Therapeutics Inc.
Bears Say
Development Re-evaluationThe company is re-evaluating further development of ‘P11 (novel psilocybin) as part of its prioritization efforts.
Uncertain Financial OutlookThe company ended the year with $27M in cash, and additional data and updates from the pipeline are awaited before making any substantive comments regarding the pipeline assets.
Valuation ConcernsAt this point, the product is not being added into the valuation, and the recommendation remains Market Perform.
Relmada Therapeutics News
RLMD FAQ
What was Relmada Therapeutics’s price range in the past 12 months?
Relmada Therapeutics lowest stock price was $0.24 and its highest was $5.12 in the past 12 months.
What is Relmada Therapeutics’s market cap?
Relmada Therapeutics’s market cap is $284.53M.
When is Relmada Therapeutics’s upcoming earnings report date?
Relmada Therapeutics’s upcoming earnings report date is Mar 24, 2026 which is in 43 days.
How were Relmada Therapeutics’s earnings last quarter?
Relmada Therapeutics released its earnings results on Nov 13, 2025. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.424 by $0.124.
Is Relmada Therapeutics overvalued?
According to Wall Street analysts Relmada Therapeutics’s price is currently Undervalued.
Does Relmada Therapeutics pay dividends?
Relmada Therapeutics does not currently pay dividends.
What is Relmada Therapeutics’s EPS estimate?
Relmada Therapeutics’s EPS estimate is -0.15.
How many shares outstanding does Relmada Therapeutics have?
Relmada Therapeutics has 73,333,626 shares outstanding.
What happened to Relmada Therapeutics’s price movement after its last earnings report?
Relmada Therapeutics reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.424. Following the earnings report the stock price went up 1.804%.
Which hedge fund is a major shareholder of Relmada Therapeutics?
Currently, no hedge funds are holding shares in RLMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Relmada Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.00 (131.96% Upside)
$9.00 (131.96% Upside)
Blogger Sentiment
Bullish
RLMD Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $161.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 5.5%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
1034.50%
12-Months-Change
Fundamentals
Return on Equity
-196.79%
Trailing 12-Months
Asset Growth
-73.30%
Trailing 12-Months
Company Description
Relmada Therapeutics
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
RLMD Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was overwhelmingly positive, highlighting significant achievements in clinical trials, regulatory alignment, and financial stability. The only notable concern was the reduction in cash reserves prior to the recent capital raise, which has since been addressed.View all RLMD earnings summariesRLMD Stock 12 Month Forecast
Average Price Target
$9.00
▲(131.96% Upside)
Technical Analysis
Ownership Overview
4.10% Insiders
0.84% Mutual Funds
0.40% Other Institutional Investors
93.48% Public Companies and
Individual Investors